Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | NRAS |
| Variant | G115Efs*46 |
| Impact List | frameshift |
| Protein Effect | loss of function - predicted |
| Gene Variant Descriptions | NRAS G115Efs*46 indicates a shift in the reading frame starting at amino acid 115 and terminating 46 residues downstream causing a premature truncation of the 189 amino acid Nras protein (UniProt.org). Due to the loss of the CAAX motif (PMID: 6087162, PMID: 21924373), G115Efs*46 is predicted to lead to a loss of Nras protein function resulting in inactivation of downstream signaling. |
| Associated Drug Resistance | |
| Category Variants Paths |
NRAS mutant NRAS exon4 NRAS G115Efs*46 NRAS mutant NRAS inact mut NRAS G115Efs*46 |
| Transcript | NM_002524.5 |
| gDNA | chr1:g.114709677delC |
| cDNA | c.344delG |
| Protein | p.G115Efs*46 |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_002524.5 | chr1:g.114709677delC | c.344delG | p.G115Efs*46 | RefSeq | GRCh38/hg38 |
| NM_002524.4 | chr1:g.114709677delC | c.344delG | p.G115Efs*46 | RefSeq | GRCh38/hg38 |
| NM_002524 | chr1:g.114709677delC | c.344delG | p.G115Efs*46 | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| NRAS G115Efs*46 | colorectal cancer | predicted - resistant | Cetuximab | Clinical Study - Cohort | Actionable | In a retrospective analysis, NRAS G115Efs*46 was identified at a frequency of >1% in 3 of 23 patients with metastatic colorectal cancer who did not respond to anti-EGFR therapy (Erbitux (cetuximab), n=12 or Vectibix (panitumumab), n=11), and was associated with a lack of response (p=0.029) to EGFR-targeted therapy (PMID: 32796636). | 32796636 |
| NRAS G115Efs*46 | colorectal cancer | predicted - resistant | Panitumumab | Clinical Study - Cohort | Actionable | In a retrospective analysis, NRAS G115Efs*46 was identified at a frequency of >1% in 3 of 23 patients with metastatic colorectal cancer who did not respond to anti-EGFR therapy (Erbitux (cetuximab), n=12 or Vectibix (panitumumab), n=11), and was associated with a lack of response (p=0.029) to EGFR-targeted therapy (PMID: 32796636). | 32796636 |